An Open Comparative Clinical Trial to Evaluate the Efficacy and Safety of Siddha Drugs Panchamuga Chendhuram and Kundavaadhi Thailam in Psoriasis

Abstract

Aim: The patients with psoriasis, like those with other major medical disorders, have reduced levels of employment and income as well as a decreased quality of life. The treatments such as methotrexate, cyclosporine have been used for many years, but the safety profile of this treatment is minimal. Hence an idea is created to conduct a clinical trial to assess the efficacy and safety of Siddha trial drugs "Panchamuga Chendhuram" (PMC) and "Kundavaadhi Thailam" (KVT) in the management of psoriasis. Materials and methods: 40 patients of either sex was divided into 2 groups. The Group I treated with PMC alone at 65mg dose twice daily, for 48 days. The Group II treated with both PMC and KVT. Efficacy was determined by a percentage reduction in Psoriasis Area and Severity Index (PASI) score. Safety of drug PMC was evaluated by measuring LFT and RFT. Results: PASI Score Mean and SEM (n) at 48 th day after treatment with the trial drug PMC alone and with both PMC and KVT were 2.295 ± 0.531 * (20), 5.305 ± 1.982 * (20) respectively, and P value <0.001 is statistically significant. Safety parameters such as T. Bilirubin (P < 0.05), T. Protein (P = 0.361), SGPT (P = 0.798), SGOT (P < 0.05), ALP (P = 0.436), urea (P= 0.810), creatinine (P = 0.207), uric acid (P = 0.836) were also have no changes before and after treatment. Conclusion: Hence it is concluded that the drugs were effective and safe in psoriasis patients.